Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | CX-2051 |
Synonyms | |
Therapy Description |
Limited information is currently available on CX-2051, a putative EpCAM-targeting antibody-drug conjugate (ADC) (Mar 2024). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CX-2051 | CX2051|CX 2051 | Limited information is currently available on CX-2051, a putative EpCAM-targeting antibody-drug conjugate (ADC) (Mar 2024). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06265688 | Phase I | CX-2051 | First In Human Study of CX-2051 in Advanced Solid Tumors | Recruiting | USA | 0 |